Equities Analysts Offer Predictions for Lucira Health, Inc.’s Q1 2023 Earnings (NASDAQ:LHDX)

Lucira Health, Inc. (NASDAQ:LHDX – Get Rating) – Equities researchers at William Blair issued their Q1 2023 EPS estimates for Lucira Health in a research report issued on Thursday, May 12th. William Blair analyst B. Weinstein anticipates that the company will post earnings per share of ($0.24) for the quarter. William Blair also issued estimates for Lucira Health’s Q2 2023 earnings at ($0.68) EPS, Q3 2023 earnings at ($0.73) EPS and Q4 2023 earnings at ($0.50) EPS.

Lucira Health (NASDAQ:LHDX – Get Rating) last issued its earnings results on Thursday, May 12th. The company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.48. Lucira Health had a negative net margin of 21.47% and a negative return on equity of 10.20%. During the same quarter in the previous year, the business earned ($0.54) EPS.

LHDX has been the topic of a number of other research reports. Lifesci Capital raised shares of Lucira Health from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 22nd. Zacks Investment Research cut shares of Lucira Health from a “buy” rating to a “hold” rating in a report on Thursday.

LHDX stock opened at $2.66 on Monday. Lucira Health has a fifty-two week low of $2.42 and a fifty-two week high of $11.10. The firm’s 50-day simple moving average is $3.29 and its 200 day simple moving average is $5.05. The stock has a market cap of $106.00 million, a PE ratio of -2.61, a price-to-earnings-growth ratio of 0.08 and a beta of 0.62.

In other news, insider Erik T. Engelson acquired 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 15th. The shares were acquired at an average price of $3.00 per share, with a total value of $90,000.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Qube Research & Technologies Ltd bought a new position in Lucira Health in the 4th quarter valued at about $557,000. Pura Vida Investments LLC boosted its position in shares of Lucira Health by 150.5% during the 3rd quarter. Pura Vida Investments LLC now owns 1,001,942 shares of the company’s stock valued at $7,615,000 after purchasing an additional 601,942 shares in the last quarter. Ieq Capital LLC boosted its position in shares of Lucira Health by 58.5% during the 4th quarter. Ieq Capital LLC now owns 73,205 shares of the company’s stock valued at $630,000 after purchasing an additional 27,030 shares in the last quarter. Eclipse Ventures LLC bought a new position in shares of Lucira Health during the 4th quarter valued at about $53,587,000. Finally, EPIQ Capital Group LLC boosted its position in shares of Lucira Health by 1.5% during the 4th quarter. EPIQ Capital Group LLC now owns 13,996,250 shares of the company’s stock valued at $120,508,000 after purchasing an additional 200,067 shares in the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Lucira Health Company Profile (Get Rating)

Lucira Health, Inc, a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits.

Read More